Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma

The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (MEKi), which represent a standard treatment for BRAF-mutant melanoma. In oligoprogressive melanoma patients with BRAF mutations, target therapy can be combined with loco-regional radiotherapy (RT). Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Ernesto, Schinzari, Giovanni, Cellini, Francesco, Balducci, Mario, Pasqualoni, Mariangela, Maiorano, Brigida Anna, Fionda, Bruno, Longo, Silvia, Deodato, Francesco, Di Stefani, Alessandro, Peris, Ketty, Gambacorta, Maria Antonietta, Tortora, Giampaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953646/
https://www.ncbi.nlm.nih.gov/pubmed/36830931
http://dx.doi.org/10.3390/biomedicines11020394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953646/
https://www.ncbi.nlm.nih.gov/pubmed/36830931
http://dx.doi.org/10.3390/biomedicines11020394

Ejemplares similares